TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22438298

Group type: EXPERIMENTAL
Intervention: 3-month exercise training program (T; n = 15)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nontrained group (NT; n = 13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (C; n = 8)
Number of subjects: 24
Study: 20844421

Group type: EXPERIMENTAL
Intervention: Intermittent muscle retraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous muscle retraction
Number of subjects: 40
Study: 18828199

Group type: EXPERIMENTAL
Intervention: Cognitive intervention and exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lumbar fusion and postoperative rehabilitation
Number of subjects: 0
Study: 15806059

Group type: EXPERIMENTAL
Intervention: Multilevel temperature-controlled radiofrequency tissue ablation (TCRFTA)
Number of subjects: 29
Study: 12773446

Group type: EXPERIMENTAL
Intervention: Follitropin beta administered by a pen device
Number of subjects: 200

Group type: COMPARATOR
Intervention: Follitropin alpha administered by a conventional syringe
Number of subjects: 200
Study: 10556614

Group type: EXPERIMENTAL
Intervention: Unexpected words from the expected semantic category presented to the right visual field (left hemisphere)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unexpected endings presented to both visual fields
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unexpected endings presented to the left visual field (right hemisphere)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Context processing in the right hemisphere
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Context processing in the left hemisphere
Number of subjects: 0
Study: 9170039

Group type: EXPERIMENTAL
Intervention: 3He MRI imaging in healthy volunteers
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3He MRI imaging in patients with chronic obstructive lung disease or bronchiectasis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3He MRI imaging in patients with bronchogenic carcinoma, chronic empyema, lymphadenopathy, or pleural effusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 3He MRI
Number of subjects: 18
Study: 1492932

Group type: EXPERIMENTAL
Intervention: Eflornithine (400 mg/kg daily, continuous intravenous infusion)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cotrimoxazole (3.84 g twice daily, intravenously)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Eflornithine (400 mg/kg daily)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cotrimoxazole (7.68 g daily)
Number of subjects: 98
Study: 3887955

Group type: EXPERIMENTAL
Intervention: Whole-gut lavage
Number of subjects: 121

Group type: COMPARATOR
Intervention: Enemas and purgatives
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Colostomy closure
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Remaining procedures excluding colostomy closure
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 121
Study: 30529930

Group type: EXPERIMENTAL
Intervention: CT angiography
Number of subjects: 9486

Group type: COMPARATOR
Intervention: Stress testing
Number of subjects: 9486

Group type: EXPERIMENTAL
Intervention: Catheterization
Number of subjects: 9486

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 9486

Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 9486

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 9486
Study: 30203749

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 160

Group type: COMPARATOR
Intervention: Allopurinol (Control)
Number of subjects: 160
Study: 26936480

Group type: EXPERIMENTAL
Intervention: Youth mentor-led nutritional intervention (BHCK); bi-weekly interactive sessions delivered by 16 youth leaders.
Number of subjects: 0
Study: 25074318

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 66

Group type: COMPARATOR
Intervention: Voglibose
Number of subjects: 66
Study: 22392001

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle modification program
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Imaging technology (positron emission tomography) for risk stratification
Number of subjects: 1300
Study: 19249751

Group type: EXPERIMENTAL
Intervention: Intranasal cocaine self-administration (1.0 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 10
Study: 17878772

Group type: EXPERIMENTAL
Intervention: 8-session structured group format memory rehabilitation program
Number of subjects: 12

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 12
Study: 15354898

Group type: EXPERIMENTAL
Intervention: Computer-imaging simulation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resin-based composite/esthetic preview/mock-up
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Photographs of other patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diagnostic models with wax setups
Number of subjects: 24
Study: 11684981

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 45
Study: 8098220

Group type: EXPERIMENTAL
Intervention: 10 mg of bisoprolol daily for two weeks
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3101553

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate eye ointment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31568587

Group type: EXPERIMENTAL
Intervention: Low-dose exercise (150 minutes per week)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: High-dose exercise (300 minutes per week)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (<75 minutes per week)
Number of subjects: 116
Study: 29277462

Group type: EXPERIMENTAL
Intervention: Parent education through home visits by trained community health workers
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Formula feeding
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Breastfeeding for ≥2 months
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Father living with mother at prenatal visit
Number of subjects: 100
Study: 28551073

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks (80 mg after a 160 mg starting dose)
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks (80 mg after a 160 mg starting dose)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 4 weeks
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Ixekizumab every 2 weeks
Number of subjects: 363
Study: 26228487

Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 22846777

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.3 mg liraglutide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.6 mg liraglutide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.2 mg liraglutide
Number of subjects: 10
Study: 21905751

Group type: EXPERIMENTAL
Intervention: Mixed nuts consumption (30 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study: 18652688

Group type: EXPERIMENTAL
Intervention: GK 420
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Remstar Auto
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Autoset Spirit
Number of subjects: 16

Group type: COMPARATOR
Intervention: Other devices (not specified)
Number of subjects: 16
Study: 16492236

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 783

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 783
Study: 14633540

Group type: EXPERIMENTAL
Intervention: BIS-guided
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: AEP-guided
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 10673488

Group type: EXPERIMENTAL
Intervention: Radiological guidelines sent to GPs in the intervention group (33 practices) with feedback after 9 months.
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control practices (36 practices) received the guidelines at the end of the study.
Number of subjects: 69
Study: 9393746

Group type: EXPERIMENTAL
Intervention: Nicotinamide (80 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Carbogen breathing
Number of subjects: 10
Study: 7504854

Group type: EXPERIMENTAL
Intervention: 3.5% oxypolygelatine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 200/0.5
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 10% dextran 40
Number of subjects: 28

Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 28
Study: 3616496

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Cefotaxime plus netilmicin
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (Cefotaxime)
Number of subjects: 93
Study: 29747583

Group type: EXPERIMENTAL
Intervention: WeCareAdvisor (WCA)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 57
Study: 28253920

Group type: EXPERIMENTAL
Intervention: Image-guided intensity-modulated radiotherapy (10x3Gy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventionally fractionated external beam radiotherapy (10x3Gy)
Number of subjects: 0
Study: 26142600

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (T&A)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (children with SDB without NE)
Number of subjects: 37
Study: 24005608

Group type: EXPERIMENTAL
Intervention: Mekabu fucoidan (MF) 300 mg/d
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 21411551

Group type: EXPERIMENTAL
Intervention: LB03002
Number of subjects: 152
Study: 20120397

Group type: EXPERIMENTAL
Intervention: Isotretinoin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 85
Study: 17418538

Group type: EXPERIMENTAL
Intervention: Guided discontinuation strategy
Number of subjects: 128

Group type: COMPARATOR
Intervention: Maintenance treatment
Number of subjects: 128
Study: 15298073

Group type: EXPERIMENTAL
Intervention: NCX-701 (nitric oxide-releasing derivative of paracetamol)
Number of subjects: 0
Study: 11703886

Group type: EXPERIMENTAL
Intervention: Serotonin agents
Number of subjects: 0
Study: 8990428

Group type: EXPERIMENTAL
Intervention: Partially home-based moderate-intensity aerobic exercise program (30 minutes, 3-4 times weekly at 70% of estimated maximal heart rate)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No exercise (control group maintained current activity level)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Partially home-based moderate-intensity aerobic exercise program
Number of subjects: 33
Study: 8491069

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 15 mg/kg acetaminophen
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen and 15 mg/kg acetaminophen
Number of subjects: 39
Study: 3574862

Group type: EXPERIMENTAL
Intervention: Etidocaine 1%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lidocaine 2% and Bupivacaine 0.75%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 29180522

Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir combination regimen for 8 weeks in DAA-treatment-naive GT1a (n=4), GT1b (n=128), and GT2 (n=97) noncirrhotic patients.
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir combination regimen for 12 weeks in DAA-treatment-naive GT1b (n=38) and GT2 (n=20) patients with compensated cirrhosis.
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir combination regimen for 12 weeks in DAA-experienced patients (n=33).
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir combination regimen for 12 weeks in GT3-infected patients (n=12).
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Baseline prevalence of NS3-D168E, NS5A-L31M, and NS5A-Y93H in DAA-naive GT1b-infected patients.
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Baseline prevalence of NS3-D168E/T/V and NS5A-L31F/I/M/V in DAA-experienced GT1b-infected patients.
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Impact of common baseline polymorphisms in NS3 and/or NS5A on treatment outcomes.
Number of subjects: 332
Study: 27179823

Group type: EXPERIMENTAL
Intervention: Withdrawal Exposure with Withdrawal Regulation Training (WT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Relaxation Control (RC)
Number of subjects: 80
Study: 25278714

Group type: EXPERIMENTAL
Intervention: Magnetic imaging-assisted colonoscopy (MIC)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 253
Study: 24368060

Group type: EXPERIMENTAL
Intervention: early modified IPS intervention in addition to treatment-as-usual
Number of subjects: 324

Group type: COMPARATOR
Intervention: treatment-as-usual alone
Number of subjects: 324
Study: 21329267

Group type: EXPERIMENTAL
Intervention: Evidence-based stimulation programme on early literacy skills, duration: 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups (English first language (L1) and ELL control groups)
Number of subjects: 0
Study: 17967917

Group type: EXPERIMENTAL
Intervention: DHA-PQ (piperaquine phosphate at 20 mg/kg/day for 3 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: CQ-SP (chloroquine at 10 mg base/kg/day for 3 days with a single dose of sulfadoxine-pyrimethamine)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DHA-PQ (piperaquine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: CQ-SP (chloroquine)
Number of subjects: 42

Group type: COMPARATOR
Intervention: DECQ (active metabolite of chloroquine)
Number of subjects: 42
Study: 15827587

Group type: EXPERIMENTAL
Intervention: Training programme
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 14655921

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Novel Bilevel (NBL) therapy
Number of subjects: 27
Study: 10394523

Group type: EXPERIMENTAL
Intervention: Combined stimulation (clomiphene citrate plus human menopausal gonadotropin)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Ultrashort stimulation (gonadotropin releasing hormone agonist plus hMG or FSH)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Long downregulation protocol
Number of subjects: 834
Study: 8892490

Group type: EXPERIMENTAL
Intervention: Composite system using 10 in- and post-hospital variables
Number of subjects: 2830

Group type: COMPARATOR
Intervention: In-hospital data only system
Number of subjects: 2830
Study: 2049748

Group type: EXPERIMENTAL
Intervention: PVC plus RT (procarbazine, vincristine, and lomustine with whole-brain irradiation)
Number of subjects: 171

Group type: COMPARATOR
Intervention: PVC alone (procarbazine, vincristine, and lomustine without whole-brain irradiation)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: PVC plus RT
Number of subjects: 171

Group type: COMPARATOR
Intervention: PVC alone
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Age, Karnofsky index, areas of Grade 2, and absence of extensive necrosis in the tumor
Number of subjects: 171
Study: 6429406

Group type: EXPERIMENTAL
Intervention: TPN with EAA (2.3 g of nitrogen per day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: TPN with ENAA (11.3 g of nitrogen per day)
Number of subjects: 11
Study: 31577219

Group type: EXPERIMENTAL
Intervention: Laparoscopic supracervical hysterectomy (LASH)
Number of subjects: 660

Group type: COMPARATOR
Intervention: Second-generation endometrial ablation (EA)
Number of subjects: 660
Study: 29364338

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (Whiteness HP Maxx 35% ‐ FGM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (GIII and GIV)
Number of subjects: 60
Study: 26833396

Group type: EXPERIMENTAL
Intervention: VR exposure therapy (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional OST (n = 50)
Number of subjects: 100
Study: 24065327

Group type: EXPERIMENTAL
Intervention: Cryptococcal antigen (CRAG) lateral flow assay (LFA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pretreatment LFA titers
Number of subjects: 0
Study: 22790961

Group type: EXPERIMENTAL
Intervention: 80% oxygen
Number of subjects: 434

Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 434
Study: 19832909

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-coated toothbrush filaments
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control toothbrushes
Number of subjects: 64
Study: 18046926

Group type: EXPERIMENTAL
Intervention: Prandial premixed insulin analogues (70% or 75% basal and 30% or 25% rapid-acting insulin analogue)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prandial premixed insulin analogues (50% basal and 50% rapid-acting insulin analogue)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal insulin analogues
Number of subjects: 0
Study: 15031136

Group type: EXPERIMENTAL
Intervention: Exercise (three 45-min bouts of cycle ergometry each night)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonexercise control condition
Number of subjects: 18
Study: 11921591

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 15

Group type: COMPARATOR
Intervention: Paracetamol (washout period)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All NSAIDs
Number of subjects: 15
Study: 9778324

Group type: EXPERIMENTAL
Intervention: Directional atherectomy followed by coronary stenting
Number of subjects: 71
Study: 7834869

Group type: EXPERIMENTAL
Intervention: Chronic pancreatitis patients
Number of subjects: 29

Group type: COMPARATOR
Intervention: Outwardly healthy Sowetans
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sowetan patients vs Manchester controls
Number of subjects: 29
Study: 3047900

Group type: EXPERIMENTAL
Intervention: Mucoregulatory agents
Number of subjects: 8
Study: 31651545

Group type: EXPERIMENTAL
Intervention: Continue ART (CTART)
Number of subjects: 939

Group type: COMPARATOR
Intervention: Discontinue ART (DCART)
Number of subjects: 939
Study: 30914496

Group type: EXPERIMENTAL
Intervention: Gas mask with cartridge A (3.5 cm H2O inspiratory resistance)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Gas mask with cartridge B (2.2 cm H2O inspiratory resistance)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline without gas mask
Number of subjects: 8
Study: 28355362

Group type: EXPERIMENTAL
Intervention: 6.0% hydrogen peroxide (White Class with calcium - FGM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide (White Class with calcium - FGM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide (Oral B 3D White - Oral-B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group - placebo
Number of subjects: 30
Study: 26632500

Group type: EXPERIMENTAL
Intervention: AC TightRope fixation (TR group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Bosworth screw fixation (BS group)
Number of subjects: 68
Study: 23698019

Group type: EXPERIMENTAL
Intervention: 1 injection of lidocaine (0.5%)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 5 injections of lidocaine (0.5%)
Number of subjects: 108

Group type: COMPARATOR
Intervention: 1 injection of saline (NaCl 0.9%)
Number of subjects: 108

Group type: COMPARATOR
Intervention: 5 injections of saline (NaCl 0.9%)
Number of subjects: 108
Study: 20518813

Group type: EXPERIMENTAL
Intervention: Effervescent tablets
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ultrasonic device
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Effervescent tablets and ultrasonic device
Number of subjects: 77

Group type: COMPARATOR
Intervention: Brushing with water (control)
Number of subjects: 77
Study: 18348774

Group type: EXPERIMENTAL
Intervention: Tinidazole (single dose of 50 mg/kg)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Nitazoxanide (7.5 mg/kg twice a day for 3 days)
Number of subjects: 166
Study: 15940095

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention for alcohol plus a booster (1 ED session plus booster session)
Number of subjects: 539

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention for alcohol plus a booster (n=34 motor vehicle crash patients)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Standard care (n=46 motor vehicle crash patients)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Brief intervention (1 ED session)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Standard care (non-motor vehicle crash patients)
Number of subjects: 539
Study: 11954681

Group type: EXPERIMENTAL
Intervention: Most important interventions for primary problems
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: All interventions including the most important and adjunctive ones
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Most important interventions for secondary problems
Number of subjects: 211
Study: 9649967

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ad libitum smoking
Number of subjects: 5

Group type: COMPARATOR
Intervention: Abstinence
Number of subjects: 5
Study: 7650235

Group type: EXPERIMENTAL
Intervention: Butorphanol nasal spray (1 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Butorphanol nasal spray plus sumatriptan (1 mg butorphanol + 6 mg SC sumatriptan)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Butorphanol nasal spray
Number of subjects: 24
Study: 2654406

Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75